insights_auto
Why is 22UA down 2,42%?
Dive Deeperchevron_right
22UA:ETR
BioNTech SE - ADR
78,60 €
arrow_downward
-2,42%(-1,95) 1D
16 հոկ, 17:35:51 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
80,75 €
High
81,15 €
Low
78,40 €
Mkt. cap
22,03 մլրդ
Avg. vol.
26,41 հզր
Volume
12,88 հզր
52-wk high
105,70 €
52-wk low
68,30 €
No. of employees
8 հզր
Open
80,75 €
High
81,15 €
Low
78,40 €
Mkt. cap
22,03 մլրդ
Avg. vol.
26,41 հզր
Volume
12,88 հզր
52-wk high
105,70 €
52-wk low
68,30 €
No. of employees
8 հզր
News stories
From web sources and news partners
24/7 Wall St.
·
14 ժամ առաջ
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Pluang
·
2 օր առաջ
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
3 օր առաջ
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR